A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2018
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Pharmacogenomic; Registrational
- Acronyms ELIOS
- Sponsors AstraZeneca
- 26 Sep 2018 Trial design of the study presented at the 19th World Conference on Lung Cancer.
- 31 Aug 2018 Biomarkers information updated
- 19 Jun 2018 Planned End Date changed from 30 Nov 2022 to 14 Nov 2022.